
Kontigo Care - Positive outlook, new products in sight

Redeye sees that Kontigo Care's Q3 report came in close to our estimates, showing top-line growth of c12% y/y. However, seasonality effects and the completion of a pilot project held back growth on a q/q basis. We continue to see a potential upside in the share, with a Base Case of SEK10.8, and we argue that Kontigo Care offers attractive exposure to the e-health sector and preventative health.

[Read more and download the Research Update.](#)

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking.

Attachments

[Kontigo Care - Positive outlook, new products in sight](#)